Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 9/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | SI | P14410 | 3/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21499708 | 0.94 | COMT (0.33) | TRPC5MDM2P2RX3CCNCCDK8 | |
| SCHEMBL18834622 | 0.91 | P2RX3 (0.35) | TRPC5P2RX3CCNCCDK8 | |
| SCHEMBL18835240 | 0.89 | TRPC5 (0.47) | TRPC5P2RX3TRPC4 | |
| SCHEMBL18834470 | 0.86 | TRPC5 (0.35) | TRPC5GAAP2RX3ALDH1A1 | |
| SCHEMBL18834542 | 0.84 | P2RX3 (0.31) | MDM2GAAP2RX3ALDH1A1 | |
| SCHEMBL20432456 | 0.83 | TRPC5 (0.43) | TRPC5MDM2KDM4E | |
| SCHEMBL19375606 | 0.79 | P2RX3 (0.37) | TRPC5P2RX3KCNH2TRPC4 | |
| SCHEMBL21316348 | 0.78 | ALDH1A1 (0.40) | TRPC5KDM4EALDH1A1 | |
| SCHEMBL18834253 | 0.76 | ADORA3 (0.46) | GAAALDH1A1HPGD | |
| SCHEMBL20432382 | 0.75 | TRPC5 (0.40) | TRPC5P2RX3KCNH2TRPC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885MDM2 4153/4885GRIN1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.